Clindamycin
Acromegaly .6 AIDS .6 Alcoholism.7 Alzheimer's Disease .7 Anorexia nervosa 8 Anxiety .8 Arthritis.9 Asthma.9 Atrial fibrillation.10 Attention Deficit Disorder .11 Blood Pressure .12 Bronchitis .13 Bulimia Nervosa.13 Cancer .14 Cardiomyopathy.15 Cerebral Palsy .15 Cerebrovascular Accident.16 Cirrhosis of the Liver .17 Cholesterol.18 Chronic Obstructive Pulmonary Disease COPD ; or Chronic Obstructive Lung Disease COLD ; . 18 Chronic Fatigue Syndrome .19 Congenital Heart Disease .20 Coronary Artery Disease see heart attack ; Coronary Artery Disease Risk Factors.21 Crohn's Disease .21 Cushing's Syndrome.21 Cystic Fibrosis.22 Cystitis .23 Dementia .23 Depression.23 Diabetes.24 Diverticulosis Diverticulitis.31 Drug Abuse.32 Echocardiography .33.
Objective: To describe the characteristics of 8 Neisseria gonorrhoeae grown from the urine of 8 patients negative in a cppB gene nucleic-acid amplification assay NAA ; . Methods: Suspensions of 8 gonococci GC ; , cultured from urine which failed to test positive in a cppB gene-based NAA performed on the same urine, were re-examined in the original NAA and by the AMPLICOR, LCx and BDProbeTec NAA. The auxotype, serotype and MICs of the 8 GC, originally cultured to provide GC isolates for susceptibility surveillance, were determined by standard methods to establish their extended phenotype. The urine samples were also re-examined in a second laboratory by the original NAA. Results: All 8 GC were phenotypically indistinguishable, proline requiring Pro- ; , of serovar IBrpyut and with identical MICs to 5 antibiotics. The original urine samples and suspensions of cultured GC were all negative on repeat testing in the cppB gene-based assay, but positive in all 3 commercial NAAs. Conclusions: Suspensions of known PAUauxotrophic GC were previously reported to yield negative cppB gene-based NAAs. The cppB gene is usually located on a cryptic plasmid, but this plasmid is often absent in PAUGC. This study documents false-negative cppB gene-based NAA both in clinical samples and from culture suspensions of the same non-PAU- GC. NAAs amplifying targets other than the cppB gene were positive when organism suspensions were tested. Problems with NAA for confirmation of gonorrhoea include a high false positive rate for the AMPLICOR NAA compared with the cppB gene-based NAA. This study suggests that some additional positive results in the AMPLICOR NAA were actually due to falsenegative results in the cppB gene-based NAA. These observations, and the requirement for cultures for susceptibility testing as a public health measure, mean that culture-based systems for obtaining viable gonococci should continue to be maintained, for example, clindamycin sinus infection.
Not only that, but it provides the right drug at the right time, in the right dose, for the right organs.
Treatment of Malaria Uncomplicated chloroquine-sensitive P. vivax and chloroquine-sensitive P. falciparum should be treated with a 3-day course of chloroquine. Uncomplicated chloroquine-resistant P. falciparum can be treated with mefloquine or oral quinine plus pyrimethamine sulfadoxine P S ; or clindamycin. A recent study has suggested that high-dose mefloquine treatment is associated with increased risk of fetal death. ; In the Amazon Basin and Southeast Asia, P S may not be effective. Falciparum malaria contracted in Thailand can be treated with quinine and clindamycin, but quinine-resistant malaria is increasing in this region. Atovaquone proguanil Malarone ; is rated Cataegory C for use in pregnancy, and should be used only if the potential benefits outweigh the possible risks. Complicated falciparum malaria requires parenteral therapy with quinidine plus doxycycline or clindamycin. Appropriate treatment to save the mother takes precedence over concerns about drug-related fetal toxicity, and individual circumstances will dictate what regimen is best in a given situation. When possible, malaria in pregnancy is best treated by an expert in this area. Radical Cure Primaquine should not be used during pregnancy because it may precipitate glucose-6-PD-induced hemolytic anemia in the fetus. If you have been treated for P. vivax or P. ovale malaria, you should continue chloroquine prophylaxis until after delivery when you can be treated with primaquine.
TO THE EDITOR: We report the appearance of erythromycin and inducible clindamycin resistance in the south-west Pacific strain of non-multiresistant methicillin-resistant Staphylococcus aureus, which has recently appeared in eastern Australia. Infections occur predominantly in Polynesian people and are usually community-acquired. Most strains belong to Western Samoan phage patterns WSPP1 or WSPP2 ; and pulsotype A when typed by pulsed-field gel electrophoresis.1, 2 These strains are resistant to all -lactams, but are usually susceptible to erythromycin, clindamycin, gentamicin, tetracycline, trimethoprimsulfamethoxazole and ciprofloxacin. Although most of these antibiotics would not be recommended for therapy, 3 clindamycin has been recommended for non-parenteral treatment of soft-tissue and bone infections, as it is efficacious in treating similar infections caused by methicillin-susceptible S. aureus.4 Twenty isolates of community-acquired, non-multiresistant pulsotype A MRSA were collected from patients from southern Brisbane and Logan in 1997 and 1998.2 A further 16 isolates were obtained from Ipswich patients between December 1998 and February 2001. We found that all 36.
I. Treatment recommendations for acute bacterial sinusitis of mild severity in adults who have not used antibiotics in previous 4 to 6 weeks. First-line Therapy Amoxicillin clavulanate Amoxicillin 1.5-3 g d ; Cefpodoxime proxetil Cefuroxime axetil If B-lactam allergic Trimethoprim sulfamethoxazole Doxycycline Azithromycin Erythromycin Predicted Efficacy % ; 93.3 88.8 86.7 Switch Options Gatiflox levoflox moxiflox, or reevaluate patient Amoxicillin clavulanate, cefpodoxime, cefixime, or gatiflox levoflox moxiflox Amoxicillin, clindamycin, or gatiflox levoflox moxiflox, Amoxicillin clavulanate, gatiflox levoflox or combination therapy Amoxicillin clavulanate Glatiflox levoflox moxiflox, or combination therapy and clobetasol.
Ceftizoxime 1 g vial Epocelin ; Ceftriaxone 500 mg vial Rocephin ; Cefotaxime Na 250 mg vial Claforan ; Ceftazidime 1 g vial Fortum ; Chlorambucil 2 mg tab Chloramphenicol 1 g vial Chlorpheniramine, Glycyrrhizine, Orotic Acid tab Orolisin ; Chlorpromazine 50 mg tab Climara 50 Estradiol 3.8 mg patch ; Climen 21 tab pk Estradiol & Cyproterone Cleo eye drop 0.3 %, 3.5 ml bt Tobramycin ; Cleocin-T Soln 1 %, 30 ml Lindamycin ; Clopine 25 mg tab Clozapine ; Clopran 25 mg tab Clomipramine ; Clomiphene 50 mg tab Clomipramine 25 mg tab Combivent 20 120 mcg dose Ipratropium Salbutamol ; Metered Aerosol Combivir tab Lamivudine 150mg & Zidovudine 300mg ; Corangin SR 40 mg tab Isosorbide Mononitrate ; Corgard 80 mg tab Nadolol ; Cytotect 2500 U 50 ml amp Human CMV immunoglobulin ; Cytotec 200 ug tab Misoprostol ; U-Miso ; Deca 0.5 mg tab Dexamethasone Decaris 50 mg tab Levamisole ; Dihydroergotamine 5 mg cap Dihydroergotoxine 1.5 mg tab Dilantin 100 mg cap Phenytoin ; Dianlin 10 mg 2 ml amp Diazepam ; Ergonovine Maleate 0.2 mg tab Ergotamine & Caffeine tab Cafergot ; Estradiol & Cyproterone 21 tab pk Climen ; Estradiol & Norethisterone 28 tab pk Sevina ; Estrodiol 1mg & Norethisterone 0.5 mg 28 tab pk Activelle ; Estrogen & Medroxyprogesterone 28 tab pk Premelle ; Estrogens, Conjugated 0.625 mg tab Premarin ; Flucon 200 mg 100 ml bt Fluconazole ; Flucon oph susp 0.1 %, 5 ml bt Fluorometholone ; Fludiazepam 0.25 mg tab Flunitrazepam 1 mg tab Flurazin 5 mg tab Trifluoperazine ; Flunarizine 5 mg tab Suzin ; Folic acid 5 mg tab Folinic Acid 50 mg vial Glibenclamide 5 mg tab Gliclazide 30 mg tab Glimepiride 2 mg tab Glipizide 5 mg tab Glucobay 50 mg tab Acarbose ; Glucophage 500 mg tab Metformin ; Glucosamine 250 mg cap.
The following is a Partial list of PC Professionals most commonly used Generic drugs along with their brand counter parts for your information. * If your prescription is for a generic medication, you will pay the lowest copay. BRAND ADALAT CC ALDACTONE ALESSE ALLEGRA ANTIVERT ATARAX ATIVAN AUGMENTIN BACTRIM DS CALAN CARDIZEM CD CARDURA CATAPRES CLEOCIN COUMADIN DARVOCET-N DELTASONE DESYREL DILACOR XR DYAZIDE ELAVIL ESTRACE FIORICET FLAGYL FLEXERIL FOLVITE GLUCOPHAGE GLUCOTROL HYDRODIURIL HYTRIN IMDUR INDERAL K-DUR K-TABS KEFLEX KENALOG KLONOPIN LASIX LOPID LOPRESSOR MEDROL METHOTREXATE GENERIC NIFEDIPINE SPIRONOLACTONE AVIANE FEXOFENADINE MECLIZINE HYDROXYZINE HCL LORAZEPAM AMOXICILLIN K-CLAVULANATE SMZ TMP DS VERAPAMIL CARTIA XT DOXAZOSIN CLONIDINE CLINDAMYCIN WARFARIN PROPO-N APAP PREDNISONE TRAZODONE DILTIAZEM XR TRIAM HCTC AMITRIPTYLINE ESTRADIOL BUTALBITAL APAP CAFFEINE METRONIDAZOLE CYCLOBENZAPRINE FOLIC ACID METFORMIN GLIPIZIDE HYDROCHLOROTHIAZIDE TERAZOSIN ISOSORBIDE MONO PROPRANOLOL KLOR-CON M20 POT CHLORIDE CEPHALEXIN TRIAMCINOLONE CLONAZEPAM FUROSEMIDE GEMFIBROZIL METOPROLOL METHYLPREDNISOLONE METHOTREXATE BRAND MICRONASE MINOCIN MOTRIN NAPROSYN NORINYL PAMELOR PEPCID PERCOCET PHENERGAN PHENERGAN CODEINE PRILOSEC PRINIVIL PRINZIDE PROVENTIL PROVERA PROZAC REGLAN RELAFEN RESTORIL ROBAXIN SOMA SUMYCIN TENORMIN TESSALON PERLES TRIMOX TRIPHASIL 21 TYLENOL CODEINE ULTRAM VALIUM VASOTEC VEETIDS VIBRAMYCIN VICODIN VOLTAREN XANAX ZANAFLEX ZANTAC ZIAC ZOVIRAX ZYLOPRIM GENERIC GLYBURIDE MINOCYCLINE IBUPROFEN NAPROXEN NECON NORTRIPTYLINE FAMOTIDINE OXYCOD APAP PROMETHAZINE PROMETH CODEINE OMEPRAZOLE LISINOPRIL LISINOPRIL HCTZ ALBUTEROL MEDROXYPROGESTERONE AC FLUOXETINE METOCLOPRAMIDE NABUMETONE TEMAZEPAM METHOCARBAMOL CARISOPRODOL TETRACYCLINE ATENOLOL BENZONATATE AMOXICILLIN TRIVORA-28 APAP CODEINE TRAMADOL HCL DIAZEPAM ENALAPRIL PENICILLN VK DOXYCYCL HYCLATE HYDROCO APAP DICLOFENAC ALPRAZOLAM TIZANIDINE RANITIDINE BISOPROLOL HCTZ ACYCLOVIR ALLOPURINOL and clotrimazole.
Please note the following: You should not uninstall the ComponentDBInstall and TableCreationCompatibility components because other components might be dependent on them. The ClassifiedEnhancements component must be uninstalled before the RecordsManagement component. Disable all components to be uninstalled, restart the content server, then uninstall them. The procedures in this section assume you installed all components.
Table 5. Change or addition of antibiotics in 22 patients. Ampicillin to cefuroxime Ampicillin to erythromycin Ampicillin to aminoglycoside Ampicillin to tetracycline Ampicillin to cloxacillin Ampicillin to erythromycin and cloxacillin Ampicillin to erythromycin and metronidazole Ampicillin to erythromycin and aminoglycoside Penicillin to tetracycline Erythromycin to cefuroxime Erythromycin to aminoglycoside Ampicillin and clindamycin to aminoglycoside, ceftaxidime and erthromycin Cefuroxime and aminoglycoside to tetracycline Total 4 5 2 and cutivate. Traditionally, clindamycin and bactrim are not effective against hospital-acquired mrsa infections, indicating the well described change in antibiotic sensitivity to the community-acquired organism. Concomitant disease CRP mg l ; WBC 109 l ; % band forms 194 10.2 72.5 CT Duplex sonography Flucloxacillin 2 gr iv days + netilmicin 100 mg iv q 8 h days, then co-amoxiclav 1.2 gr iv q days, followed by co-amoxiclav 625 mg tid 10 days Flucloxacillin 2 gr iv days + netilmicin 150 mg q 12 h 14 days, then ciprofloxacin 750 mg po bid 14 days Flucloxacillin 2 gr iv days + amikacin 750 mg iv q 24 h days + clindamycin 500 mg iv q 18 h days 10 3 Diagnostic Imaging Therapy Time to defervescence days ; * Length of hospital stay days ; 47 Follow-up and cyproheptadine.
Medications Cheap Drugs
Although previous years have seen a pattern of declining losses, it is gratifying to report that the commercial potential of our drug delivery technologies is now reflected in profitability, for example, clindamycin and breastfeeding.
Prophylaxis for dental, respiratory and oesophageal procedures is directed against viridans streptococci. While these are not the only organisms that cause bacteraemia following these procedures, they are the organisms most likely to cause endocarditis. In contrast, for gut, genitourinary, obstetric and gynaecological procedures, Enterococcus spp. e.g. Enterococcus faecalis ; are the important organisms. In the last few years there have been many reports of viridans streptococci with reduced susceptibility to penicillins.3 In Auckland, for example, only 50% of isolates remain fully susceptible, and many are only inhibited rather than killed by penicillin.5 These strains are typically less susceptible to cephalosporins also, especially the oral first-generation cephalosporins presently available in New Zealand e.g. cephradine, cephalexin, cefaclor ; . Because viridans streptococci remain more susceptible to the oral second-generation cephalosporins, we have recommended one of them, cefuroxime axetil, as an option.3 The principles of prophylaxis have been established in animal models. Most of the available data for these principles are for viridans streptococci. This is appropriate given their pre-eminent role in potentially preventable endocarditis. We generally extrapolate from these principles for other organisms. Successful prophylaxis is not necessarily nor simply dependent on the prevention of bacteraemia. Prolonged antibacterial activity over many hours is the common background requirement for maximal efficacy with most agents. The most effective single-dose prophylactic regimens against viridans streptococcal experimental endocarditis are synergistic killing regimens e.g. a penicillin or cephalosporin plus an aminoglycoside, or vancomycin used alone ; . However, bacteriostatic or sublethal non-killing ; regimens are also very effective if continued for long enough. For example, either clindamycin or clarithromycin provide effective prophylaxis against viridans streptococcal endocarditis if given for a prolonged duration. These drugs replace erythromycin in our current recommendations because of their greater efficacy in experimental animals, 6 more predictable pharmokinetics, and fewer gastrointestinal side-effects. Clarithromycin is the only oral agent recommended as a single dose because of its extremely long half-life of about 12 hours. Prophylaxis must begin just before the procedure. If it is begun hours or days beforehand, it may select strains of decreased susceptibility so that if endocarditis occurs it is more difficult to treat and diclofenac.
Overall thrombolysis results in an absolute increase of early death of 5.4% p 0.00001 ; [Number to Harm 19] The increase in early death is attributable to intracerebral haemorrhage The absolute increase risk of early death with t-PA is 1.5% [95CI -0.1 to 5.0] p 0.3, for example, clindamycin colitis!
PERIANAL AND PERIRECTAL ABSCESS AND CELLULITIS IN PATIENTS WITH MALIGNANT DISEASE Agents: Escherichia coli, Group D Streptococcus, Bacteroides fragilis, Clostridium, Klebsiella pneumoniae, Pseudomonas aeruginosa 55% of patients with acute leukemia; 50% case-fatality rate in these cases ; , Proteus mirabilis, Citrobacter freundii, Staphylococcus aureus, Enterobacter cloacae, Candida albicans Diagnosis: swab culture Treatment: ceftazidime + clindamycin, piperacillin + tobramycin + clindamycin; + vancomycin if progression; + surgery if inadequate response PERIANAL CELLULITIS IN YOUNG CHILDREN Agent: Streptococcus pyogenes Diagnosis: culture of anal swab Treatment: phenoxymethylpenicillin 10 mg kg to 500 mg orally 6 hourly for 7 d PSOAS ABSCESS: ? 12 reported cases y worldwide; predisposing conditions diabetes, immunosuppression, renal failure Agents: Staphylococcus aureus 80% of primary ; , Pseudomonas aeruginosa, Haemophilus aphrophilus, Proteus mirabilis, Escherichia coli, Streptococcus viridans, ? -haemolytic streptococci, Enterobacter, Salmonella enteritidis, Enterococcus , Serratia marcescens, Bacteroides fragilis, Mycobacterium tuberculosis uncommon ; , Mycobacterium kansasii, Mycobacterium xenopi, Pasteurella multocida, Salmonella typhi rare ; , Candida tropicalis, Torulopsis glabrata Diagnosis: computerised tomography; Gram stain and culture of aspirate; culture of blood and urine Treatment: surgical drainage + : Staphylococcus aureus: cloxacillin Streptococci, Pasteurella multocida: penicillin Serratia marcescens: gentamicin Anaerobes: metronidazole Mycobacterium tuberculosis: isoniazid 10 mg kg to 300 mg orally once daily or 15 mg kg to 600 mg orally 3 times weekly for 6 mo [ pyridoxine 25 mg breastfed baby 5 mg ; orally with each dose] + rifampicin 10 mg kg to 600 mg orally once daily 1 h before breakfast or 15 mg kg to 600 mg orally 3 times a week for 6 mo + pyrazinamide 25-35 mg kg to 2 g orally once daily or 50 mg kg to 3 g orally 3 times weekly for 2 mo 6 not known to be susceptible to isoniazid and rifampicin ; + ethambutol 15 mg kg orally daily not 6 y or plasma creatinine 160 M L; regular ocular monitoring ; or 30 mg kg orally 3 times weekly for 2 mo or unt il known to be susceptible to isonazid and rifampicin to 6 mo ; Salmonella typhi: ciprofloxacin 1.5 g d orally Candida, Torulopsis: amphotericin B Organism Not Known: cloxacillin + gentamicin + cljndamycin INTRAABDOMINAL ABSCESS: 12% from pancreatitis, 10-20% from appendicitis, 10% from genitourinary tract, 8% from biliary tract, 7% from diverticulitis, 3% from trauma, 3% from perforating tumours, 2% from peptic ulcer, 2% from leaking suture line, 15-30% from miscellaneous sources, 10% from unknown source Agents: 80-95% Bacteroides fragilis, 80-95% Escherichia coli, 60% Enterococcus, 50% anaerobic streptococci, 50% Clostridium, 40% Fusobacterium, 38% Proteus; Eikenella corrodens, other Bacteroides, Prevotella, Desulphovibrio desulfuricans Diagnosis: fever in 82%, abnormal chest film in 61%, abdominal pain in 38%, persistent drainage in 18%, abnormal plain film of abdomen in 14%, chest dullness in 12%, abdominal mass by palpation in 7%; liver-lung scan 98% accurate ; , CT scan 98% accurate ; , ultrasound 96% accurate ; , gallium scan 82% accurate culture of aspirate or surgical specimen Treatment: clindamycin, chloramphenicol PERINEPHRIC ABSCESS Agents: Staphylococcus 36% of cases in renal transplant recipients ; , aerobic Gram negative bacilli 32% of cases in renal transplant recipients ; , anaerobes 28% of cases in renal transplant recipients ; , Candida albicans 4% of cases in renal transplant recipients ; , Mycobacterium intracellulare Diagnosis: fever, abdominal tenderness; computed tomography, intravenous pyelogram, cystogram; culture of material obtained by surgery or percutaneous drainage Treatment: surgical drainage + appropriate antimicrobials PELVIC ABSCESS, PELVIC INFLAMMATORY DISEASE, PARAMETRITIS: 62% salpingitis, 22% normal findings, 5% ovarian cysts, 4% ectopic pregnancy, 3% appendicitis, 1% endometriosis; important cause of ectopic pregnancy, sterility and tuboovarian abscess; increasing importance in Australia and other developed nations; vaginal douching a risk factor Agents: Neisseria gonorrhoeae, Chlamydia trachomatis 1 4 of the million recognised cases in USA each year ; , Bacteroides, anaerobic Gram positive cocci, Escherichia coli, Actinomyces israelii almost exclusively associated with use of IUD ; , Mycoplasma hominis, Ureaplasma urealyticum, Haemophilus influenzae IUD related and maternal ; , Streptococcus pyogenes, Streptococcus milleri, Streptococcus pneumoniae IUD, recent birth, gynecologic surgery ; , Clostridium perfringens, Candida associated with suture, IUD and dimenhydrinate. Use the main Keyword Search for fast access to your information request. The Keyword Search looks for all documents containing indexed terms matching your keywords in both the care & condition and drug document databases. See "Keyword Search" on page 13 for more information on how to use this page.
Clindamycin medicine
Health claims in the languages of all member states, even if they intend to market the product in only one or two countries. There are also concerns about the likely length and cost of the approval process. There is considerable opposition to the restrictions on implied health claims. If a claim which makes reference to psychological or behavioural functions or general good health can be scientifically substantiated, then is it really in consumers' best interests for it to be prohibited? Some in the food industry believe that, although unintended, the innovation and development of foods that can benefit consumers' health will be stifled by this ban. With nearly a quarter of the UK population suffering from obesity, the restriction on claims which make reference to weight control or slimming, and that are scientifically substantiated, may not be in consumers' interests. The ban on endorsements by health professionals and charities has also been criticised by those who believe such partnerships can play a positive role in the promotion of public health. The elimination of inaccurate and unsubstantiated health and nutrition claims on foods is clearly to be welcomed. However, there is a real danger that over zealousness will undermine good intentions by making labels overly complex and by preventing genuine claims from being communicated. It is little wonder that proposals for the speedy implementation of the regulation are being resisted. It must be hoped that amendments will be accepted that secure a sensible balance between protecting consumers and allowing substantiated and beneficial claims to be made. q David McIntosh and Olya Melnitchouk, Davies Arnold Cooper, London. Drug Desloratidine Neo-Clarityn ; Eptifibatide Integrillin ; Fentanyl, oral transmucosal Actiq ; Gemcitabine Gemzar ; Gentamicin + Clindqmycin bone cement Copal ; Gliclazide M R Diamicron MR ; Glimepiride Amaryl ; Imitinab Glivec ; Levetiracetam Keppra ; Indication Seasonal allergic rhinitis Chronic idiopathic urticaria Acute coronary syndrome Breakthrough pain in palliative care Pancreatic cancer Orthopaedic surgery; high risk one stage revisions and cemented implants Type 2 diabetes mellitus Type 2 diabetes mellitus Chronic myeloid leukaemia 3rd line adjunctive therapy in partial seizures with or without secondary generalisation in patients refractory to 2nd line treatment Emergency hormonal contraception Specific Gram positive infections Type 2 diabetes mellitus Type 2 diabetes mellitus Obesity Acute coronary syndrome Predominantly classic subfoveal choroidal neovascularisation due to agerelated macular degeneration or secondary to pathological myopia. Date of Decision Dec 2001 March 2001 Dec 2001 Dec 2001 Dec 2001 Sept 2001 Sept 2001 Dec 2001 March 2001 Decision Category 1a 2a 2b and dramamine and clindamycin. Can Oral Controlled Drug Delivery Meet the Challenges Posed by Chronotherapeutics?. Cidofovir gel also appears effective, although the trial results were not convincing enough to win united states food and drug administration approval in may 199 intravenous cidofovir vistide ; may be another option for people with aciclovir-resistant herpes, although it is not licensed as a treatment for drug-resistant herpes in the united kingdom and enalapril. Was unable to complete protocol therapy due to adverse effects related to protocol medication, this was considered a side effect failure and were removed from the study. Reasons for non-evaluability during follow-up visits included: menstruation during therapy or at follow-up visit; received less than 3 doses clindamcin or 11 doses of metronidazole; received other antibiotic therapy; failed to return for follow-up visits between 5 to 9 and 28-35 days post therapy; douching done during therapy or within 2 days prior to any follow-up visit. Statistical Analysis Efficacy was analyzed using Yates corrected chi-square Epi Info 5. 0 ; to determine significant difference between the 2 treatment groups. A p value of 0. 05 was considered significant. RESULTS Only 33 of the 51 study participants were evaluable at the first follow-up visit 5-9 days post-therapy 16 in the clindzmycin group and 17 in the metronidazole group. Eighteen women were considered non-evaluable of whom 7 had their menstruation during protocol therapy and at follow-up visit; 6 failed to return for follow-up visit; and 5 received less than 3 doses of clindamycin and or 11 doses of metronidazole. One in each treatment group failed to return for the second follow-up visit scheduled 28 to 35 days after completion of therapy so that there were only 31 patients evaluable at the end of the study period. Baseline Parameters The mean age of the 16 women who received clindamycin was 28.1 years with an age range of 23-38 years old and was 29.1 years for the 17 women who received metronidazole with an age range of 22-48 years. Baseline parameters of both treatment groups, in terms of both symptoms and clinical parameters for BV were essentially similar, as shown in Table I. Only 4 of 16 25% ; patients treated with clindamycin and 5 of 17 29.4% ; patients treated with metronidazole had symptoms of abnormal vaginal discharge. However on speculum examination, 9 of 16 56.2% ; and 11 of 17 64.7% ; had evidence of adherent and abundant watery vaginal discharge. All the other 3 parameters required for the clinical diagnosis of BY were present in both groups, namely: vaginal fluid pH 4.5, fishy amine odor in vaginal fluid on addition of KOH positive amine test ; and presence of clue cells in vaginal discharge.
Clindamycin information
